Search

Your search keyword '"Kassim, Adetola"' showing total 939 results
Start Over Author "Kassim, Adetola"
939 results on '"Kassim, Adetola"'

1. Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia

Author

Gilmore, Rachel M., Abernathy, Karin, Shultes, Kendall, Eplin, Dwight D., Orton, Lindsay, Kassim, Adetola, Sengsayadeth, Salyka, Chinratanalab, Wichai, Kim, Tae Kon, Dholaria, Bhagirathbhai, Jayani, Reena V., Savani, Bipin N., McNeer, Elizabeth, Choi, Leena, and Gatwood, Katie

Published
2024
Full Text
View/download PDF

2. Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease

Author

Gordon, Rachel D'Amico, Welkie, Rina Li, Quaye, Nives, Hankins, Jane S, Kassim, Adetola A, Thompson, Alexis A, Treadwell, Marsha, Lin, Chyongchiou J, and Cronin, Robert M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Hematology, Clinical Research, Sickle Cell Disease, Rare Diseases, Rehabilitation, Behavioral and Social Science, Decent Work and Economic Growth, Adult, Child, Humans, United States, Absenteeism, Caregivers, Cost of Illness, Employment, Anemia, Sickle Cell, Cardiovascular medicine and haematology
Abstract

AbstractSickle cell disease (SCD) is a genetic disorder affecting 100 000 people with an estimated annual medical cost of $3 billion in the United States; however, the economic impact on patients is not well described. We aimed to examine the indirect economic burden and test the hypothesis that socioeconomic status and greater social vulnerability risks are associated with increased absenteeism and employment loss. We surveyed adults and caregivers of children with SCD at 5 US centers from 2014 to 2021. Logistic regression models were used to examine the associations of employment loss and missed days of work with demographics and social determinants. Indirect costs were estimated by multiplying the self-reported missed days of work and job loss by 2022 average wages by the state of the participating institution. Of the 244 participants, 10.3% reported employment loss in the last 5 years, and 17.5% reported missing 10 or more days of work. Adults had 3 times more employment loss compared with caregivers of children with SCD (OR, 3.18; 95% CI, 1.12-9.01) but fewer missed days of work (OR, 0.24; 95% CI, 0.11-0.0.51). Participants who did not live with a partner reported increased employment loss (OR, 4.70; 95% CI, 1.04-21.17) and more missed days of work (OR, 4.58; 95% CI, 1.04-20.15). The estimated annual indirect economic burden was $2 266 873 ($9290 per participant). Adults with SCD and caregivers of children with SCD commonly report employment loss and missed days of work as important risk factors. The high indirect economic burden suggests that future economic evaluations of SCD should include SCD-related indirect economic burden.

Published
2024

5. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Author

Kassim, Adetola A., de la Fuente, Josu, Nur, Erfan, Wilkerson, Karina L., Alahmari, Ali D., Seber, Adriana, Bonfim, Carmem, Simões, Belinda Pinto, Alzahrani, Mohsen, Eckrich, Michael J., Horn, Biljana, Hanna, Rabi, Dhedin, Nathalie, Rangarajan, Hemalatha G., Gouveia, Roseane Vasconcelos, Almohareb, Fahad, Aljurf, Mahmoud, Essa, Mohammed, Alahmari, Bader, Gatwood, Katie, Connelly, James A., Dovern, Elisabeth, Rodeghier, Mark, and DeBaun, Michael R.

Published
2024
Full Text
View/download PDF

9. Phase 2 trial of montelukast for prevention of pain in sickle cell disease

Author

Field, Joshua J, Kassim, Adetola, Brandow, Amanda, Embury, Stephen H, Matsui, Neil, Wilkerson, Karina, Bryant, Valencia, Zhang, Liyun, Simpson, Pippa, and DeBaun, Michael R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Sickle Cell Disease, Clinical Research, Chronic Pain, Hematology, Lung, Pain Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Respiratory, Acetates, Adolescent, Adult, Anemia, Sickle Cell, Cyclopropanes, Humans, Leukotriene Antagonists, Pain, Quinolines, Sulfides, Cardiovascular medicine and haematology
Abstract

Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle cell disease (SCD), levels of CysLTs are increased compared with controls and associated with a higher rate of hospitalization for pain. We tested the hypothesis that administration of the CysLT receptor antagonist montelukast would improve SCD-related comorbidities, including pain, in adolescents and adults with SCD. In a phase 2 randomized trial, we administered montelukast or placebo for 8 weeks. The primary outcome measure was a >30% reduction in soluble vascular cell adhesion molecule 1 (sVCAM), a marker of vascular injury. Secondary outcome measures were reduction in daily pain, improvement in pulmonary function, and improvement in microvascular blood flow, as measured by laser Doppler velocimetry. Forty-two participants with SCD were randomized to receive montelukast or placebo for 8 weeks. We found no difference between the montelukast and placebo groups with regard to the levels of sVCAM, reported pain, pulmonary function, or microvascular blood flow. Although montelukast is an effective treatment for asthma, we did not find benefit for SCD-related outcomes. This clinical trial was registered at www.clinicaltrials.gov as #NCT01960413.

Published
2020

10. Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease

Author

Cronin, Robert M, Yang, Manshu, Hankins, Jane S, Byrd, Jeannie, Pernell, Brandi M, Kassim, Adetola, Adams-Graves, Patricia, Thompson, Alexis A, Kalinyak, Karen, DeBaun, Michael, and Treadwell, Marsha

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Health Services, Behavioral and Social Science, Hematology, Rare Diseases, Sickle Cell Disease, Clinical Research, Good Health and Well Being, Admitting Department, Hospital, Anemia, Sickle Cell, Communication, Female, Health Personnel, Humans, Male, Provider communication, shared decision-making, vulnerable populations, health care surveys, sickle cell anemia, consumer assessment of healthcare providers and systems, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Objective: To test the hypothesis that caregivers' or adult participants' low ratings of provider communication are associated with more hospital admissions among adults and children with sickle cell disease (SCD), respectively. Secondarily, we determined whether there was an association between the caregivers' or participants' health literacy and rating of providers' communication. Methods: Primary data were collected from participants through surveys between 2014 and 2016, across six sickle cell centers throughout the U.S. In this cross-sectional cohort study, 211 adults with SCD and 331 caregivers of children with SCD completed surveys evaluating provider communication using the Consumer Assessment of Healthcare Providers and Systems (CAHPS), healthcare utilization, health literacy, and other sociodemographic and behavioral variables. Analyses included descriptive statistics, bivariate analyses, and logistic regression. Results: Participants with better ratings of provider communication were less likely to be hospitalized (odds ratio (OR) = 0.54, 95% confidence interval (CI) = [0.35, 0.83]). Positive ratings of provider communication were associated with fewer readmissions for children (OR = 0.23, 95% CI = [0.09, 0.57]). Participants with better ratings of provider communication were less likely to rate their health literacy as lower (regression coefficient (B) = -0.28, 95% CI = [-0.46, -0.10]). Conclusions: Low ratings of provider communication were associated with more hospitalizations and readmissions in SCD, suggesting the need for interventions targeted at improving patient-provider communication which could decrease hospitalizations for this population.

Published
2020

11. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings

Author

Farrell, Ann T, Panepinto, Julie, Desai, Ankit A, Kassim, Adetola A, Lebensburger, Jeffrey, Walters, Mark C, Bauer, Daniel E, Blaylark, Rae M, DiMichele, Donna M, Gladwin, Mark T, Green, Nancy S, Hassell, Kathryn, Kato, Gregory J, Klings, Elizabeth S, Kohn, Donald B, Krishnamurti, Lakshmanan, Little, Jane, Makani, Julie, Malik, Punam, McGann, Patrick T, Minniti, Caterina, Morris, Claudia R, Odame, Isaac, Oneal, Patricia Ann, Setse, Rosanna, Sharma, Poornima, and Shenoy, Shalini

Subjects
Orphan Drug, Clinical Research, Pain Research, Sickle Cell Disease, Chronic Pain, Hematology, Patient Safety, Rare Diseases, Clinical Trials and Supportive Activities, Neurosciences, Good Health and Well Being, Anemia, Sickle Cell, Heart Diseases, Humans, Lung Diseases, Renal Insufficiency, Chronic
Abstract

To address the global burden of sickle cell disease and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to patient-reported outcome, pain (non-patient-reported outcomes), the brain, end-organ considerations, biomarkers, measurement of cure, and low-resource settings. This article presents the findings and recommendations of the end-organ considerations, measurement of cure, and low-resource settings panels as well as relevant findings and recommendations from the biomarkers panel.

Published
2019

14. Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease

Author

Jordan, Lori C., primary, King, Allison A., additional, Kanter, Julie, additional, Lebensburger, Jeff, additional, Ford, Andria L., additional, Varughese, Taniya E., additional, Garrett, Lisa, additional, Mullis, Lauren, additional, Saint Jean, LeShana, additional, Davis, Samantha, additional, Dumas, Jeanine, additional, Kassim, Adetola A., additional, Rodeghier, Mark, additional, Hikima, Mustapha S., additional, Suwaid, Mohammad A., additional, Saleh, Mohammed K., additional, and DeBaun, Michael R., additional

Published
2024
Full Text
View/download PDF

15. Long-term outcomes after cardiac transplantation in AL amyloidosis.

Author

Lessans, Spencer, primary, Patel, Vivek, additional, Dholaria, Bhagirathbhai R., additional, Jayani, Reena, additional, Sengsayadeth, Salyka M., additional, Wigger, Mark, additional, Peltier, Amanda, additional, Horst, Sara, additional, Schlendorf, Kelly, additional, Hung, Rebecca, additional, Goodman, Stacey, additional, Savani, Bipin N., additional, Kassim, Adetola, additional, Bhaskar, Shakthi, additional, Biltibo, Eden, additional, Jallouk, Andrew Philip, additional, Siddiqi, Hasan, additional, Harrell, Shelton, additional, Baljevic, Muhamed, additional, and Punnoose, Lynn, additional

Published
2024
Full Text
View/download PDF

16. Flat dose intravenous immunoglobulin (IVIG) for primary infection prophylaxis after CAR-T for B-cell non-Hodgkin lymphoma (B-NHL).

Author

Lessans, Spencer, primary, Zenner, Morgan, additional, Dholaria, Bhagirathbhai R., additional, Kassim, Adetola, additional, Jayani, Reena, additional, Biltibo, Eden, additional, Bhaskar, Shakthi, additional, Morgan, David S., additional, Savani, Bipin N., additional, Oluwole, Olalekan O., additional, Baljevic, Muhamed, additional, and Patel, Vivek, additional

Published
2024
Full Text
View/download PDF

17. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.

Author

Cornell, Robert, Ky, Bonnie, Weiss, Brendan, Dahm, Cherie, Gupta, Deepak, Du, Liping, Carver, Joseph, Cohen, Adam, Engelhardt, Brian, Garfall, Alfred, Goodman, Stacey, Harrell, Shelton, Kassim, Adetola, Jadhav, Trafina, Jagasia, Madan, Moslehi, Javid, OQuinn, Rupal, Savona, Michael, Slosky, David, Smith, Amanda, Stadtmauer, Edward, Vogl, Dan, Waxman, Adam, and Lenihan, Daniel

Subjects
Adult, Aged, Aged, 80 and over, Bortezomib, Cardiovascular Diseases, Disease-Free Survival, Electrocardiography, Female, Heart Diseases, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Molecular Targeted Therapy, Multiple Myeloma, Natriuretic Peptide, Brain, Neoplasm Recurrence, Local, Oligopeptides, Prospective Studies, Proteasome Inhibitors, Risk Factors, Time-to-Treatment, Treatment Outcome, Troponin I, Troponin T
Abstract

PURPOSE: Cardiovascular adverse events (CVAEs) can occur during proteasome inhibitor (PI) therapy. We conducted a prospective, observational, multi-institutional study to define risk factors and outcomes in patients with multiple myeloma (MM) receiving PIs. PATIENTS AND METHODS: Patients with relapsed MM initiating carfilzomib- or bortezomib-based therapy underwent baseline assessments and repeated assessments at regular intervals over 6 months, including cardiac biomarkers (troponin I or T, brain natriuretic peptide [BNP], and N-terminal proBNP), ECG, and echocardiography. Monitoring occurred over 18 months for development of CVAEs. RESULTS: Of 95 patients enrolled, 65 received carfilzomib and 30 received bortezomib, with median 25 months of follow-up. Sixty-four CVAEs occurred, with 55% grade 3 or greater in severity. CVAEs occurred in 51% of patients treated with carfilzomib and 17% of those treated with bortezomib (P = .002). Median time to first CVAE from treatment start was 31 days, and 86% occurred within the first 3 months. Patients receiving carfilzomib-based therapy with a baseline elevated BNP level higher than 100 pg/mL or N-terminal proBNP level higher than 125 pg/mL had increased risk for CVAE (odds ratio, 10.8; P < .001). Elevated natriuretic peptides occurring mid-first cycle of treatment with carfilzomib were associated with a substantially higher risk of CVAEs (odds ratio, 36.0; P < .001). Patients who experienced a CVAE had inferior progression-free survival (log-rank P = .01) and overall survival (log-rank P < .001). PI therapy was safely resumed in 89% of patients, although 41% required chemotherapy modifications. CONCLUSION: CVAEs are common during PI therapy for relapsed MM, especially with carfilzomib, particularly within the first 3 months of therapy. CVAEs were associated with worse overall outcomes, but usually, discontinuation of therapy was not required. Natriuretic peptides were highly predictive of CVAEs; however, validation of this finding is necessary before uniform incorporation into the routine management of patients receiving carfilzomib.

Published
2019

18. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study

Author

Cronin, Robert M, Hankins, Jane S, Byrd, Jeannie, Pernell, Brandi M, Kassim, Adetola, Adams-Graves, Patricia, Thompson, Alexis, Kalinyak, Karen, DeBaun, Michael, and Treadwell, Marsha

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Sickle Cell Disease, Pediatric, Health Services, Rare Diseases, Behavioral and Social Science, Hematology, Pain Research, Good Health and Well Being, Adolescent, Adult, Age Factors, Anemia, Sickle Cell, Child, Cross-Sectional Studies, Female, Humans, Male, Mental Health, Patient Readmission, Socioeconomic Factors, United States, Health care utilization, clinic visits, vulnerable populations, health care surveys, sickle cell disease, hospital admissions, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

ObjectiveHospital admissions are significant events in the care of individuals with sickle cell disease (SCD) due to associated costs and potential for quality of life compromise.MethodsThis cross-sectional cohort study evaluated risk factors for admissions and readmissions between October 2014 and March 2016 in adults with SCD (n = 201) and caregivers of children with SCD (n = 330) at six centres across the U.S. Survey items assessed social determinants of health (e.g. educational attainment, difficulty paying bills), depressive symptoms, social support, health literacy, spirituality, missed clinic appointments, and outcomes hospital admissions and 30-day readmissions in the previous year.ResultsA majority of adults (64%) and almost half of children (reported by caregivers: 43%) were admitted, and fewer readmitted (adults: 28%; children: 9%). The most common reason for hospitalization was uncontrolled pain (admission: adults: 84%, children: 69%; readmissions: adults: 83%, children: 69%). Children were less likely to have admissions/readmissions than adults (Admissions: OR: 0.35, 95% CI: [0.23,0.52]); Readmissions: 0.23 [0.13,0.41]). For all participants, missing appointments were associated with admissions (1.66 [1.07, 2.58]) and readmissions (2.68 [1.28, 6.29]), as were depressive symptoms (admissions: 1.36 [1.16,1.59]; readmissions: 1.24 [1.04, 1.49]). In adults, difficulty paying bills was associated with more admissions, (3.11 [1.47,6.62]) readmissions (3.7 [1.76,7.79]), and higher spirituality was associated with fewer readmissions (0.39 [0.18,0.81]).DiscussionMissing appointments was significantly associated with admissions and readmissions. Findings confirm that age, mental health, financial insecurity, spirituality, and clinic attendance are all modifiable factors that are associated with admissions and readmissions; addressing them could reduce hospitalizations.

Published
2019

20. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial

Author

Abdullahi, Shehu U, Jibir, Binta W, Bello-Manga, Halima, Gambo, Safiya, Inuwa, Hauwa, Tijjani, Aliyu G, Idris, Nura, Galadanci, Aisha, Hikima, Mustapha S, Galadanci, Najibah, Borodo, Awwal, Tabari, Abdulkadir M, Haliru, Lawal, Suleiman, Aisha, Ibrahim, Jamila, Greene, Brittany C, Ghafuri, Djamila L, Rodeghier, Mark, Slaughter, James C, Kirkham, Fenella J, Neville, Kathleen, Kassim, Adetola, Trevathan, Edwin, Jordan, Lori C, Aliyu, Muktar H, and DeBaun, Michael R

Published
2022
Full Text
View/download PDF

22. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

26. Transcranial doppler velocity in iron‐deficient Nigerian children with sickle cell anemia

Author

Abdullahi, Shehu Umar, primary, Sunusi, Surayya, additional, Aminu, Hauwa, additional, Umar, Rashida, additional, Abba, Mohammed Sani, additional, Jibir, Binta W., additional, Sani, Saifuddeen, additional, Gambo, Safiya, additional, Bello‐Manga, Halima, additional, Galadanci, Najibah A., additional, Covert Greene, Brittany, additional, Kassim, Adetola A., additional, Jordan, Lori C., additional, Aliyu, Muktar H., additional, Rodeghier, Mark, additional, DeBaun, Michael R., additional, and Volanakis, Emmanuel J., additional

Published
2024
Full Text
View/download PDF

28. Continuous Infusion Vs Intermittent Bolus Mesna with Post-Transplant Cyclophosphamide Following Hematopoietic Stem Cell Transplantation

Author

Orton, Lindsay, primary, Gatwood, Katie S., additional, Biltibo, Eden, additional, Jallouk, Andrew, additional, Jerkins, James H., additional, Jayani, Reena V, additional, Dholaria, Dr. Bhagirathbhai, additional, Kim, Tae K Kon, additional, Savani, Bipin N., additional, Choi, Leena, additional, McNeer, Elizabeth, additional, and Kassim, Adetola A., additional

Published
2024
Full Text
View/download PDF

30. Interim Analysis of Prospective Clinical Trial of Outpatient Administration of Axicabtagene Ciloleucel in High-Grade B Cell Lymphoma

Author

Dholaria, Dr. Bhagirathbhai, primary, Bhaskar, Shakthi T, additional, Patel, Vivek G., additional, Biltibo, Eden, additional, Sengsayadeth, Salyka, additional, Jallouk, Andrew, additional, Jerkins, James H., additional, Baer, Brittney, additional, Ali, Nur, additional, Morgan, David, additional, Baljevic, Muhamed, additional, Savani, Bipin N., additional, Kassim, Adetola A., additional, and Oluwole, Olalekan O., additional

Published
2024
Full Text
View/download PDF

31. Excellent Outcomes Using a Non-Myeloablative Conditioning with Thiotepa and Post -Transplant Cyclophosphamide in Adults Undergoing a Matched Related Donor Bone Marrow Transplant for Severe Sickle Cell Disease

Author

Alasbali, Reem, primary, Alzahrani, Mohsen, additional, Alhayli, Saud, additional, Rasheed, Walid K., additional, Wilkerson, Karina, additional, Fakih, Riad El, additional, AlAhmari, Bader, additional, Samarkandi, Hadeel, additional, Albabtain, Abdulwahab, additional, Alotaibi, Ahmad, additional, Ahmed, Syed O, additional, Saad, Ayman, additional, Alzahrani, Hazzaa, additional, Almohareb, Fahad, additional, Aljurf, Mahmoud, additional, Kassim, Adetola A., additional, and AlAhmari, Ali, additional

Published
2024
Full Text
View/download PDF

36. Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Author

Kassim, Adetola A., primary, Walters, Mark C., additional, Eapen, Mary, additional, Ritzau, Nicole, additional, Smith, Madoc, additional, Solh, Melhem M., additional, McKinney, Christopher, additional, Nieder, Michael, additional, Ross, Maureen, additional, Kent, Michael, additional, Abusin, Ghada, additional, Mallhi, Kanwaldeep K., additional, Silva, Jorge Galvez, additional, Shaughnessy, Paul, additional, Kanter, Julie, additional, Haines, Hilary, additional, Farah, Rafic J, additional, Khaled, Yasser, additional, Abraham, Allistair, additional, Bollard, Catherine M., additional, Cooke, Kenneth R., additional, de La Fuente, Josu, additional, Hanna, Rabi, additional, Horowitz, Mary M., additional, Jordan, Lori C, additional, Krishnamurti, Lakshmanan, additional, Leifere, Eric, additional, Mahadeo, Kris Michael, additional, Shenoy, Shalini, additional, Ritzau, Nicole M., additional, DeBaun, Michael R., additional, and Brodsky, Robert A., additional

Published
2023
Full Text
View/download PDF

44. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

49. Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium

Author

Iqbal, Madiha, Reljic, Tea, Corbacioglu, Selim, de la Fuente, Josu, Gluckman, Eliane, Kumar, Ambuj, Yassine, Farah, Ayala, Ernesto, El-Jawahri, Areej, Murthy, Hemant, Almohareb, Fahad, Hashmi, Shahrukh K., Cappelli, Barbara, Alahmari, Ali, Scigliuolo, Graziana Maria, Kassim, Adetola, Aljurf, Mahmoud, and Kharfan-Dabaja, Mohamed A.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results